[
1. 1.Nicolas D, Kerndt CC, Reed M. Sacubitril/Valsartan. [Updated 2020 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507904/
]Search in Google Scholar
[
2. ENTRESTO Rezumatul Caracteristicilor Produsului 2019.
]Search in Google Scholar
[
3. 3.Senni M, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep;18(9):1193-202. doi: 10.1002/ejhf.548.10.1002/ejhf.548508481227170530
]Search in Google Scholar
[
4. Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020 Oct;8(10):844-855. doi: 10.1016/j.jchf.2020.06.015. Epub 2020 Sep 9. PMID: 32919916.10.1016/j.jchf.2020.06.01532919916
]Search in Google Scholar
[
5. Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, Anand IS, van Veldhuisen DJ, Kober L, Janssens S, Cleland JGF, Pieske B, Rouleau JL, Zile MR, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020 Nov;22(11):2093-2101. doi: 10.1002/ejhf.1984. Epub 2020 Sep 30. PMID: 32840930.10.1002/ejhf.198432840930
]Search in Google Scholar
[
6. Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.
]Search in Google Scholar
[
7. PROVE-HF, ClinicalTrials.gov number, NCT02887183
]Search in Google Scholar
[
8. Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.
]Search in Google Scholar